prostate cancer – Medxy AI

AI Foundation Model Revolutionizes Non-Invasive Diagnosis and Grading of Prostate Cancer

By MedXY 09/03/2025

A multidisciplinary Chinese team has developed an AI-driven MRI-pathology foundation model that enables accurate, non-invasive diagnosis and grading of prostate cancer, significantly improving clinical decision-making and reducing unnecessary biopsies.

Medical News Wellness & Lifestyle

Frequent Ejaculation and Prostate Cancer Risk: Insights from a Landmark Harvard Study

By MedXY 09/01/2025

A large Harvard study shows men ejaculating 21+ times monthly have a significantly reduced overall risk of prostate cancer, especially low-risk forms, across different life stages.

Clinical Updates Wellness & Lifestyle

Statin Use and Survival Benefits in Advanced Prostate Cancer Patients Receiving Apalutamide: Insights from the TITAN and SPARTAN Trials

By MedXY 08/23/2025

Statin exposure is linked to improved overall survival in prostate cancer patients treated with apalutamide but raises the risk of severe cardiac adverse events due to underlying cardiovascular conditions.

Clinical Updates Wellness & Lifestyle

FDA Approves ArteraAI Prostate: The First AI-Driven Software Transforming Localized Prostate Cancer Management

By MedXY 08/19/2025

ArteraAI Prostate, the first FDA-approved AI-driven multimodal software, offers personalized clinical decision support for localized prostate cancer, improving treatment precision and reducing overtreatment risks.

Clinical Updates Wellness & Lifestyle

KEYNOTE-991: Pembrolizumab Does Not Improve Outcomes in Metastatic Hormone-Sensitive Prostate Cancer—A Phase III Clinical Trial Analysis

By MedXY 08/08/2025

KEYNOTE-991 shows pembrolizumab does not improve progression-free or overall survival for mHSPC, and increases serious adverse events when added to enzalutamide and ADT.

Clinical Updates

PARP inhibitors shine: How the TALAPRO-2 trial is changing the landscape of prostate cancer with precision medicine

By Dr.Paul 08/07/2025

Treatment for advanced prostate cancer has advanced significantly in the past decade, but metastatic castration-resistant…

$Early Toxicity Comparison of Moderately Hypofractionated Radiotherapy and Stereotactic Body Radiotherapy in Prostate Cancer: Insights from the PACE-C Trial$

Clinical Updates Wellness & Lifestyle

Early Toxicity Comparison of Moderately Hypofractionated Radiotherapy and Stereotactic Body Radiotherapy in Prostate Cancer: Insights from the PACE-C Trial

By MedXY 08/03/2025

The PACE-C phase 3 trial shows that stereotactic body radiotherapy (SBRT) and moderately hypofractionated radiotherapy (MHRT) have comparable early toxicity profiles in intermediate- and high-risk prostate cancer patients.

Clinical Updates Wellness & Lifestyle

Metformin in Prostate Cancer: Revisiting Hopes and Realities After Recent Phase 3 Trials

By MedXY 08/02/2025

Recent large RCTs show metformin does not improve survival or reduce metabolic syndrome risk in prostate cancer patients on ADT, though it modestly improves metabolic parameters.